| CIM21LAPP2A-4 is an intermediate-maturing, high-yielding, white maize hybrid with GLS, TLB, FSR and Ear rots resistance. The product is notable for its good husk cover, ear position, standability, good nicking, and is suitable for food use in the central mid-altitude environments of Mexico or similar agro-ecologies in other regions. |
|
General Information |
| |
Target Region |
Latin America |
| |
Adaptation/Agroecological zone |
1200 - 1800m above sea level |
| |
Type of product |
Three-way hybrid |
| |
Year first announced |
2023 |
| |
|
|
| |
Grain Characteristics |
| |
|
|
Grain color |
White |
| Abiotic Stress Performance |
|
Grain texture |
Semi-dent |
| Grain yield under optimum conditions |
11.7 t/ha |
|
|
|
| Grain yield under rainfed conditions |
8.2 t/ha |
|
Biotic Stress Performance |
| Grain yield on-farm |
9.0 t/ha |
|
Turcicum leaf blight (TLB) (1-9)* |
3.2 |
| |
|
|
Grey leaf spot (GLS) (1-9)* |
3.4 |
| Agronomic Characteristics |
|
Ear Rots (%) |
10.5% |
| Maturity group |
Intermediate |
|
Fusarium Stalk Rots (FSR) (%) |
7.9% |
| 50% anthesis |
71 DAP |
|
*Scored on 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible |
| Plant height |
268 cm |
|
| Ear height |
134 cm |
|
|
|
| Ear position (ratio) |
0.50 |
|
Seed Production Characteristics |
| Ears per plant |
0.96 |
|
SC female parent seed yield |
9.6 t/ha |
| Ear aspect (1-9)* |
3.9 |
|
Male seed yield |
4.3 t/ha |
| Plant aspect (1-9)* |
3.1 |
|
Nicking |
0 days |
| Bad husk cover |
1.4% |
|
|
|
| Root lodging |
1.6% |
|
Comments |
| Stalk lodging |
3.0% |
|
Product information is based on data from the 2021 CIMMYT Mexico Stage 4 Trials and 2022 Stage 5 Trials. Actual performance will vary depending on a number of agronomic and environmental factors.
Abbreviations:
DAP = days after planting
SC = Single-cross
TLB = Turcicum leaf blight
GLS = Grey leaf spot
FSR = Fusarium Stalk Rots |
| Anther-silking interval |
1.2 days |
|
| *Plant and ear aspects are scored on 1-9 scale, where 1 = desirable and 9 = undesirable characteristics |
|
| |
| |
|
|
| Further Links |
|
| Full Announcement & trial data |
|
| |
| |
|
|
| |
|
|
